(Reuters) - A U.S. Centers for Disease Control and Prevention (CDC) advisory panel will meet on Friday to review data on the COVID-19 vaccine developed by Pfizer Inc and BioNTech SE, with a vote ...

The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains 1 Shipping of the LP.8.1-adapted vaccine will ...

Pfizer-BioNTech asked the Food and Drug Administration to authorize an updated version of its COVID booster designed to target the BA.5 omicron subvariant, the drugmaker announced in a release Monday.

NEW YORK - Pfizer on Wednesday shared data about a third dose of its COVID-19 vaccine that suggests it "strongly" boosts protection against the more contagious delta variant of the coronavirus, which ...

NEW YORK, N.Y. — Pfizer and BioNTech announced Friday that they’re submitting new data to the Food and Drug Administration (FDA) that shows their COVID-19 vaccine can be stored at higher temperatures, ...

U.S. scientists and regulators told Pfizer July 12 that they need more data and more time to determine if COVID-19 vaccine booster shots are necessary, The New York Times reported. Pfizer ...

The FDA staff made the conclusion in briefing documents ahead of a meeting on Thursday when a panel of external advisors to the agency will discuss whether to recommend full approval of the RSV shot.

Pfizer's CEO said Sunday that the company is "days" away from submitting data to the FDA in the hopes of having its COVID-19 vaccine approved for children as young as 5. In speaking ABC News on Sunday ...